Editas MedicineEDIT -1.00%45 ROC (Joel Greenblatt) % is -503.91% as of Mar. 2026. GuruFocus rates EDIT with a GF Score™ of 45/100 and a GF Value™ of $1.86 (Significantly Overvalued). The stock has 11 warning signs investors should review. Among 1,320 Biotechnology companies, Editas Medicine ranks worse than 55.53% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Editas Medicine's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -503.91%.
The historical rank and industry rank for Editas Medicine's ROC (Joel Greenblatt) % or its related term are showing as below:
EDIT'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -506.46 Med: -396.84 Max: -285.48
Current: -440.27
During the past 13 years, Editas Medicine's highest ROC (Joel Greenblatt) % was -285.48%. The lowest was -506.46%. And the median was -396.84%.
EDIT's ROC (Joel Greenblatt) % is ranked worse than 55.53% of 1320
companies
in the Biotechnology industry
Industry Median: -294.23
vs EDIT: -440.27
Editas Medicine's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -4.10% per year.
Editas Medicine (NAS:EDIT) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Editas Medicine ROC (Joel Greenblatt) % Related Terms
Editas Medicine ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Editas Medicine's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EDIT vs SGMT, AUTL, FBRX: ROC (Joel Greenblatt) % Comparison
For the Biotechnology subindustry, Editas Medicine's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Editas Medicine ROC (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Editas Medicine's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Editas Medicine's ROC (Joel Greenblatt) % falls into.
Editas Medicine ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of -503.91% mean?
Editas Medicine (EDIT) has a ROC (Joel Greenblatt) % of -503.91% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Editas Medicine and its competitors. According to the industry distribution chart, Editas Medicine ranks #733 out of 1320 companies in the Biotechnology industry, placing it in the top 55.5%.
Is Editas Medicine's ROC (Joel Greenblatt) % too high?
Editas Medicine's current ROC (Joel Greenblatt) % is -503.91%. Based on the distribution chart, Editas Medicine ranks #733 out of 1320 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Editas Medicine has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Editas Medicine's ROC (Joel Greenblatt) % compare to SGMT and AUTL?
According to the Biotechnology industry distribution chart, Editas Medicine ranks #733 out of 1320 companies for ROC (Joel Greenblatt) %. This places Editas Medicine in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Editas Medicine and its competitors. Editas Medicine's current ROC (Joel Greenblatt) % is -503.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Editas Medicine stock overvalued right now?
Based on GuruFocus' analysis, Editas Medicine (EDIT) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.86, compared to a current price of $3.61 — trading 94.3% above its estimated fair value. The current ROC (Joel Greenblatt) % is -503.91%. Editas Medicine's overall GF Score™ is 45/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Editas Medicine (EDIT), the current ROC (Joel Greenblatt) % is -503.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Editas Medicine (EDIT) Overvalued in 2026?
Based on GuruFocus' analysis, Editas Medicine stock appears to be overvalued.
The current stock price of $3.61 is trading 94.3% above its estimated GF Value™ of $1.86.
GuruFocus considers Editas Medicine to be Significantly Overvalued.
Key valuation signals for EDIT:
ROC (Joel Greenblatt) %: -503.91%
GF Value™: $1.86 vs. price of $3.61 (94.3% above fair value)
No single metric tells the full story. See the EDIT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
45GF Score
Get the complete analysis for EDIT
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EDIT has been successfully added to your 
